Sanofi: results for phase III of Soliqua

(CercleFinance.com) - Sanofi has said that phase III results for Soliqua have shown a significant fall in glycémie sanguine compared to GLP-1 receptor agonist treatments.


Patients who switch to Soliqua have reached average blood sugar the American Diabetes Association recommended level of 7%. The full phase III data was presented at the American Diabetes Association (ADA) 79th Scientific Sessions.

This Phase III study evaluating adults with type 2 diabetes inadequately controlled by GLP-1 receptor agonist (GLP-1 RA) treatments, Soliqua/Suliqua (insulin glargine 100 Units/mL and lixisenatide) met the primary study objective by demonstrating a statistically superior reduction of average blood sugar level (HbA1c) after 26 weeks, compared with continuing GLP-1 RA treatment.

"As the first comparison between Soliqua and both daily and weekly GLP-1 RA treatments, this study provides physicians with new data that they could use when considering Soliqua as a part of a personalized treatment plan," said Rachele Berria, Global Head of Diabetes Medical Affairs at Sanofi.



Copyright (c) 2019 CercleFinance.com. All rights reserved.